LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive (<i>RET</i>+) NSCLC.
Theresa Bayt(Eli Lilly (United States)), Maximilian J. Hochmair(Karl Landsteiner Society), Jonathan W. Goldman(University of California, Los Angeles), Jacob Sands(Harvard University), Weiji Su(Eli Lilly (United States)), Lin Wu(Materials Systems (United States)), Guoping Li(North Sichuan Medical University), Xue-Ning Yang(Guangdong Academy of Medical Sciences), Hye Ryun Kim(Yonsei University), Andreas Hallqvist(Sahlgrenska University Hospital)
Cited by 0
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695